Author:
Zhuang Na,Gu Zhiyun,Feng Juan,Chai Zixuan,Shan Juanjuan,Qian Cheng
Reference41 articles.
1. Cancer statistics, 2022;Siegel;CA Cancer J. Clin.,2022
2. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature;Adnane;Methods Enzymol.,2006
3. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer;Wilhelm;Nat. Rev. Drug Discov.,2006
4. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis;Wilhelm;Cancer Res.,2004
5. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5;Liu;Cancer Res.,2006
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献